Table 2.
Patient | Time after sdNVP prior to HAART (months) | Time to failure/follow-up (months) | Viral load (log10) | CD4 count (cells/μl) | %103K (AAA) (AAG) | %103N (AAC) | %103N (AAT) | %181Y (TAT) | %181C (TGT) | Viroseq results at failure |
---|---|---|---|---|---|---|---|---|---|---|
1b,c | 10 | 6 | 5.88 | 54 | 100 | — | — | 99.76 | 0.20 | 184V/190A |
2b,c | 5.25 | 6 | 4.45 | 46 | 97.99 | 1.95 | — | 99.88 | 0.10 | 103N |
3b | 9.5 | 5.5 | 5.88 | 48 | 100 | — | — | 98.1 | 0.35 | 181C/184V |
4b | 5.5 | 5.5 | 5.88 | 22 | 95.17 | 3.14 | 1.69 | 99.85 | 0.13 | 103N/181C/184V |
5b | 3.25 | 6.75 | 4.79 | n/a | 98.96 | 0.84 | 0.20 | 99.9 | — | — |
6b | 6 | 7.5 | 5.27 | 84 | 99.98 | — | — | 99.75 | 0.24 | 103N |
7b,c | 1 | 5 | 5.31 | 151 | 99.98 | — | — | 99.6 | 0.10 | 103N |
8c | 14.75 | 24 | 3.78 | 179 | 99.94 | — | — | 99.56 | 0.14 | |
9 | 12.25 | 25 | 5.88 | 292 | 98.65 | 1.34 | — | 99.87 | 0.12 | |
10 | 19 | 22.75 | 5.88 | n/a | 99.54 | 0.45 | — | 99.56 | 0.44 | |
11 | 13.75 | 25 | 4.80 | 171 | 100 | — | — | 99.62 | 0.35 | |
12 | 8.5 | 24.5 | 5.02 | 226 | 99.99 | — | — | 99.9 | — | |
13 | 0 | 31 | 2.94 | 261 | 99.84 | — | — | 99.91 | — | |
14 | 1 | 30 | 5.47 | 117 | 93.56 | 2.44 | 4.11 | 99.69 | 0.29 | |
15 | 9.5 | 17.5 | 4.51 | n/ad | 99.98 | — | — | 99.85 | 0.13 | |
16 | 1 | 24 | 4.75 | 156 | 100 | — | — | 99.79 | — | |
17 | 7.25 | 55.75 | 5.44 | 50 | 99.98 | — | — | 99.96 | — | |
18 | 13 | 47 | 4.74 | 206 | 99.98 | — | — | 99.96 | — | |
19 | 16.5 | 41.5 | 5.88 | 246 | 99.97 | — | — | 99.8 | 0.17 | |
20c | 38.5 | 17.5 | 4.90 | 132 | 96.89 | 3.11 | — | 99.96 | — | |
21 | 7 | 54 | 5.72 | 155 | 99.99 | — | — | 99.9 | — | |
22 | 12 | 41 | 3.73 | 294 | 99.99 | — | — | 99.98 | — | |
23 | 12 | 37 | 3.48 | 200 | 99.97 | — | — | 99.92 | — | |
24 | 9.5 | 41.75 | 5.02 | 174 | 96.5 | 3.5 | — | 99.95 | — | |
25 | 7 | 45 | 5.26 | 171 | 99.99 | — | — | 99.94 | — | |
26 | 1.5 | 43 | 4.86 | 179 | 99.88 | 0.13 | — | 99.95 | — |
Patients 1–7 were those who experienced virologic failure after starting NVP-containing ART after exposure to sdNVP. Cells with dash marks represent negative results (either no mutations are present when the cloning sequence was performed or the result is below the clinical cutoff on the ASPCR assay).
Virologic failure following treatment with NVP-containing ART.
Patient with detectable resistance by cloning and sequencing.
—, data not available.